Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line - Immunotherapy

No Prior Therapy With PD-1/PD-L1

- THOR0006
  Phase I/II of Nivolumab with Vorolanib in Refractory Thoracic Tumors
  PI: Wakelee NCTN
- LUN0085
  Phase II Pembrolizumab in Metastatic Non-Squamous NSCLC Examining Circulating Tumor DNA Levels
  PI: Neal Stanford
  1st Priority
- LUN0083
  Phase I/II NKTR-214 + Nivolumab in Select Locally Advanced or Metastatic Solid Tumor Malignancies
  PI: Neal Nektar
  2nd Priority

On anti PD-1/ anti PD-L1 with response, stable disease or modest progression

- LUN0088
  Phase II Radical-Dose RT with Anti-PD-1/ Anti-PD-L1 Immunotherapy in Non-Small Cell Lung Cancer
  PI: Gensheimer Stanford

Failed Therapy PD-L1

- THOR0006
  Phase I/II of Nivolumab with Vorolanib in Refractory Thoracic Tumors
  PI: Wakelee NCTN
- LUN0107
  Phase Ib/II Grapiprant +/- Pembrolizumab in Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
  PI: Wakelee Amys Therapeutics
  NCTN

Lung Map Screening Study

- ECOC-ACRIN-S1800A
  Phase II Ramucirumab + MK3475 vs SoC in Previously Tx w/ Immunotherapy for Stage IV/Recurrent NSCLC
  PI: Neal

KEY
- Pending
- Open for Enrollment
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold